Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

AMG 386

15mg/kg

DRUG

AMG 386

30 mg/kg

DRUG

AMG 386 Placebo

AMG 386 Placebo

DRUG

Pemetrexed

Pemetrexed 500 mg/m2

DRUG

Carboplatin

Carboplatin AUC 6

Trial Locations (35)

1200

Research Site, Brussels

2031

Research Site, Randwick

2050

Research Site, Camperdown

2217

Research Site, Kogarah

2485

Research Site, Tweed Heads

3084

Research Site, Heidelberg

3165

Research Site, Bentleigh East

4029

Research Site, Herston

10461

Research Site, The Bronx

26500

Research Site, Pátrai

28046

Research Site, Madrid

29010

Research Site, Málaga

29605

Research Site, Greenville

41110

Research Site, Larissa

42003

Research Site, Paducah

50009

Research Site, Zaragoza

56429

Research Site, Thessaloniki

58501

Research Site, Bismarck

61615

Research Site, Peoria

71110

Research Site, Heraklion

71913

Research Site, Hot Springs

72703

Research Site, Fayetteville

90048

Research Site, Los Angeles

90403

Research Site, Santa Monica

92123

Research Site, San Diego

92262

Research Site, Palm Springs

94523

Research Site, Pleasant Hill

03756

Research Site, Hannover

L8V 5C2

Research Site, Hamilton

L1G 2B9

Research Site, Oshawa

K1H 8L6

Research Site, Ottawa

M4N 3M5

Research Site, Toronto

H7M 3L9

Research Site, Laval

G6V 3Z1

Research Site, Lévis

H2L 4M1

Research Site, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01666977 - Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter